Designing Phase 0 Cancer Clinical Trials

Phase 0 trials are designed primarily to evaluate the pharmacodynamic and/or pharmacokinetic properties of selected investigational agents before initiating more traditional phase I testing. One of the major objectives of phase 0 trials is to interrogate and refine a target or biomarker assay for dr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2008-06, Vol.14 (12), p.3675-3682
Main Authors: Murgo, Anthony J, Kummar, Shivaani, Rubinstein, Larry, Gutierrez, Martin, Collins, Jerry, Kinders, Robert, Parchment, Ralph E, Ji, Jiuping, Steinberg, Seth M, Yang, Sherry X, Hollingshead, Melinda, Chen, Alice, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E, Doroshow, James H
Format: Article
Language:English
Subjects:
Algorithms
Cancer drug development
Clinical Trials as Topic - methods
Drug Screening Assays, Antitumor - methods
Exploratory IND
Humans
Models, Biological
Oncology clinical trial
Pharmacodynamics
Pharmacokinetics
Phase 0
Research Design
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phase 0 trials are designed primarily to evaluate the pharmacodynamic and/or pharmacokinetic properties of selected investigational agents before initiating more traditional phase I testing. One of the major objectives of phase 0 trials is to interrogate and refine a target or biomarker assay for drug effect in human samples implementing procedures developed and validated in preclinical models. Thus, close collaboration between laboratory scientists and clinical investigators is essential to the design and conduct of phase 0 trials. Given the relatively small number of patients and tissue samples, showing a significant drug effect in phase 0 trials requires precise and reproducible assay procedures and innovative statistical methodology. Furthermore, phase 0 trials involving limited exposure of a study agent administered at low doses and/or for a short period allow them to be initiated under the Food and Drug Administration exploratory investigational new drug guidance with less preclinical toxicity data than usually required for traditional first-in-human studies. Because of the very limited drug exposure, phase 0 trials offer no chance of therapeutic benefit, which can impede patient enrollment, particularly if invasive tumor biopsies are required. The challenges to accrual are not insurmountable, however, and well-designed and executed phase 0 trials are feasible and have great potential for improving the efficiency and success of subsequent trials, particularly those evaluating molecularly targeted agents.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-07-4560